Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) EBIT Margin (2016 - 2026)

Champions Oncology (CSBR) has 16 years of EBIT Margin data on record, last reported at 1.23% in Q4 2025.

  • For Q4 2025, EBIT Margin fell 420.0% year-over-year to 1.23%; the TTM value through Oct 2025 reached 3.68%, up 515.0%, while the annual FY2025 figure was 8.0%, 2266.0% up from the prior year.
  • EBIT Margin reached 1.23% in Q4 2025 per CSBR's latest filing, up from 3.77% in the prior quarter.
  • Across five years, EBIT Margin topped out at 26.4% in Q1 2025 and bottomed at 21.45% in Q1 2024.
  • Average EBIT Margin over 5 years is 3.56%, with a median of 2.0% recorded in 2022.
  • Peak YoY movement for EBIT Margin: plummeted -2553bps in 2023, then surged 4785bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 2.23% in 2021, then crashed by -98bps to 0.05% in 2022, then crashed by -34564bps to 16.89% in 2023, then surged by 132bps to 5.43% in 2024, then crashed by -77bps to 1.23% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 1.23% in Q4 2025, 3.77% in Q3 2025, and 16.24% in Q2 2025.